- Home
- PHVS vs RILYP Comparison
PHVS vs RILYP Comparison
Compare PHVS & RILYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- RILYP
- Stock Information
- Founded
- PHVS 2015
- RILYP 1973
- Country
- PHVS Switzerland
- RILYP United States
- Employees
- PHVS N/A
- RILYP N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- RILYP Investment Managers
- Sector
- PHVS Health Care
- RILYP Finance
- Exchange
- PHVS Nasdaq
- RILYP Nasdaq
- Market Cap
- PHVS 980.3M
- RILYP N/A
- IPO Year
- PHVS 2021
- RILYP N/A
- Fundamental
- Price
- PHVS $18.60
- RILYP $2.14
- Analyst Decision
- PHVS Buy
- RILYP
- Analyst Count
- PHVS 6
- RILYP 0
- Target Price
- PHVS $37.17
- RILYP N/A
- AVG Volume (30 Days)
- PHVS 35.9K
- RILYP 16.9K
- Earning Date
- PHVS 08-13-2025
- RILYP 01-01-0001
- Dividend Yield
- PHVS N/A
- RILYP 39.51%
- EPS Growth
- PHVS N/A
- RILYP N/A
- EPS
- PHVS N/A
- RILYP N/A
- Revenue
- PHVS N/A
- RILYP $854,383,000.00
- Revenue This Year
- PHVS N/A
- RILYP N/A
- Revenue Next Year
- PHVS N/A
- RILYP N/A
- P/E Ratio
- PHVS N/A
- RILYP N/A
- Revenue Growth
- PHVS N/A
- RILYP N/A
- 52 Week Low
- PHVS $11.51
- RILYP $1.73
- 52 Week High
- PHVS $25.50
- RILYP $20.00
- Technical
- Relative Strength Index (RSI)
- PHVS 60.00
- RILYP 48.93
- Support Level
- PHVS $16.72
- RILYP $2.00
- Resistance Level
- PHVS $17.53
- RILYP $2.47
- Average True Range (ATR)
- PHVS 0.93
- RILYP 0.24
- MACD
- PHVS 0.07
- RILYP 0.05
- Stochastic Oscillator
- PHVS 92.86
- RILYP 60.14
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.